Search Results 1121-1130 of 18045 for monoclonal antibody

1. Novel SEQUEnced Immunotherapy With Anti-angiogenesis And Chemotherapy In Advanced GastroesophageaL Adenocarcinoma (SEQUEL) - Mayo Clinic

   ... monoclonal antibody or hypersensitivity to pembrolizumab or any of its excipients. - Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks ...

2. Infectious Diseases Clinical Trials - Mayo Clinic Research

   ... antibody detectable targets on cancer cells (cancer vaccines or antibody ... Monoclonal Antibodies To Treat Hospitalized Patients With COVID-19 Rochester, MN.

3. Ublituximab In Autoantibody Positive Immune Mediated Necrotizing Myopathy - Mayo Clinic

   About this study. This is a multi-center, Phase 2 trial of ublituximab as first-line combination therapy in early, active autoantibody positive ...

4. Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps

   Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6 months before V1 if the half-life is unknown. Anti-immunoglobulin E therapy ...

5. An Open-label Study To Assess The Anti-Tumor Activity And Safety Of REGN1979, An Anti-CD20 X Anti-CD3 Bispecific Antibody, In Patients With Relapsed Or Refractory B-cell Non-Hodgkin Lymphoma - Mayo Clinic

   An Open-label Study To Assess The Anti-Tumor Activity And Safety Of REGN1979, An Anti-CD20 X Anti-CD3 Bispecific Antibody, In Patients With Relapsed Or ...

6. Hepatocellular Carcinoma (HCC) Clinical Trials - Mayo Clinic Research

   The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with ...

7. Medical Research & Education - Mayo Clinic News Network

   Antibody-drug conjugates are targeted cancer therapies. They deliver potent drugs directly into cancer cells while minimizing harm to healthy tissue. These ...

8. Study To Evaluate Efficacy And Safety Of Mepolizumab For Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients - Mayo Clinic

   Monoclonal antibodies: Subjects who have received any monoclonal antibody within 5 half-lives of Visit 1. Investigational medications: Subjects who have ...

9. A Study Evaluating The Efficacy And Safety Of Obinutuzumab In Participants With Primary Membranous Nephropathy - Mayo Clinic

   History of severe allergic or anaphylactic reactions to monoclonal antibodies or known hypersensitivity to any component of the obinutuzumab infusion; ...

10. A Study Comparing CAR-T Therapy Versus Pomalidomide, Bortezomib And Dexamethasone (PVd) Or Daratumumab, Pomalidomide And Dexamethasone (DPd) In Participants With Relapsed And Lenalidomide-Refractory Multiple Myeloma - Mayo Clinic

    Monoclonal antibody treatment within 21 days. Cytotoxic therapy within 14 days. Proteasome inhibitor therapy within 14 days -Immunomodulatory drug (IMiD) ...